Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyBlue Cross Blue Shield OK — Urinary Tumor Marker C…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB038

    Urinary Tumor Markers for Bladder Cancer

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB038 alerts

    Get alerted when Policy CPCPLAB038 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines reimbursement and coding criteria for urinary biomarker tests used in diagnosis and surveillance of bladder cancer for Blue Cross Blue Shield - Oklahoma members and providers.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyUrinary Tumor Markers for Bladder Cancer
    Policy CodePolicy CPCPLAB038
    Change TypeCode removals
    Effective DateMay 1, 2026
    Last ReviewJan 12, 2026
    Next Review Date
    Key ActionReview plan-specific coverage documents and submit accurate documentation to support claims and code use.
    SourceLink
    POLICY UPDATE CHANGES

    Removed codes 0012M, 0013M, 0363U, 0420U, 0452U, 0465U, 0549U.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Adjunct reimbursable situations
    9Procedure codes listed
    1Policy update entries

    Coverage Criteria for Urinary Tumor Markers

    Reimbursable adjunct uses

    Covered when used as adjunct tests in specific clinical contexts.

    Adjunct diagnostic or surveillance use: Urinary biomarkers (bladder tumor antigen/BTA, nuclear matrix protein/NMP22, or fluorescence in situ hybridization/FISH UroVysion) are reimbursable when used as an adjunct in either: (a) diagnostic exclusion of bladder cancer for individuals with atypical or equivocal cytology, OR (b) monitoring of high-risk, non–muscle-invasive bladder cancer.

    From Reimbursement Information item 1 (a-b).

    ImmunoCyt adjunct in surveillance: Fluorescence immunocytology (ImmunoCyt/uCyt) may be reimbursable as an adjunct to cystoscopy or cytology for monitoring individuals with bladder cancer.

    From Reimbursement Information item 2.

    Not reimbursable / excluded uses

    Not reimbursable indications and exclusions.

    Excluded indications: Use of urinary biomarkers (BTA, NMP22, FISH UroVysion) or fluorescence immunocytology (ImmunoCyt/uCyt) for evaluation of hematuria, for screening asymptomatic individuals for bladder cancer, for diagnosing bladder cancer in symptomatic individuals, or for any other indications not specified as reimbursable are not reimbursable.

    From Reimbursement Information items 3 (a-b) and 4.

    Any urinary tumor markers for bladder cancer not specifically listed as reimbursable in this policy are not reimbursable. This includes any tests beyond the named assays (bladder tumor antigen/BTA, nuclear matrix protein/NMP22, UroVysion FISH, and ImmunoCyt) when used for assessment of bladder cancer. Refer to the reimbursable list for allowable adjunct uses.

    The following uses of urinary biomarkers and fluorescence immunocytology (ImmunoCyt/uCyt) are not reimbursable: evaluation of hematuria, screening asymptomatic individuals for bladder cancer, diagnosing bladder cancer in symptomatic individuals, or any other indications not specified as reimbursable in this policy. Tests billed for these excluded indications may be denied.

    Procedure and Billing Codes

    Procedure codes listedmixed
    86294
    86316
    86386
    88120
    88121
    88346
    88350
    0365U
    0366U
    0367U

    Provider Responsibilities and Billing Guidance

    Note

    Plan/product-specific requirements

    The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product; providers should review plan documents for eligible coverage for services rendered.

    • Not all lab management reimbursement criteria apply to every product — check the member's specific plan documents (e.g., Certificate of Coverage, benefit booklet, Summary Plan Description) to confirm eligibility and coverage.
    • Blue Cross and Blue Shield of Oklahoma may exercise discretion in interpreting and applying this policy; plan documents and provider contracts govern in case of conflict.
    Documentation Required

    Documentation and claims accuracy

    Providers are responsible for submission of accurate documentation and coding for services rendered. Submit claims using valid, HIPAA-approved code sets and industry coding guidelines.

    • Use correct CPT/HCPCS/ICD-10/NDC codes and follow coding manuals and CMS guidance (e.g., CCI edits, NCCI, UB, AMA CPT guidance).

    Background

    Urinary biomarkers (for example, bladder tumor antigen/BTA, nuclear matrix protein/NMP22, and UroVysion FISH) and fluorescence immunocytology (ImmunoCyt/uCyt) are adjunct tools used to aid in the diagnosis or surveillance of bladder cancer. Per the policy, these assays may be reimbursable when used as an adjunct to cytology—specifically to help exclude cancer in patients with atypical or equivocal cytology—or as adjuncts in monitoring individuals with high‑risk, non–muscle‑invasive bladder cancer, and ImmunoCyt may be used adjunctively with cystoscopy or cytology in surveillance.

    Definitions

    Inv-11: Urinary biomarkers — definitions
    Bladder Tumor Antigen (BTA)A urinary biomarker test (BTA) referenced as reimbursable when used as an adjunct in diagnostic exclusion of bladder cancer or monitoring high‑risk non–muscle‑invasive disease; listed among tests not reimbursable for hematuria evaluation, asymptomatic screening, or other unlisted indications.
    Nuclear Matrix Protein 22 (NMP22)A urinary protein marker (NMP22) used as an adjunctive test for diagnostic exclusion in cases of atypical/equivocal cytology or for surveillance of high‑risk non–muscle‑invasive bladder cancer; not reimbursable for hematuria evaluation, asymptomatic screening, diagnosis of symptomatic individuals, or other unlisted uses.
    UroVysion (FISH) Bladder Cancer testA fluorescence in situ hybridization (FISH) assay (UroVysion) cited as an adjunct reimbursable test for diagnostic exclusion with atypical cytology or monitoring high‑risk non‑muscle‑invasive bladder cancer; excluded for hematuria evaluation, asymptomatic screening, symptomatic diagnosis, and other unlisted indications.
    Fluorescence Immunocytology (ImmunoCyt/uCyt)An immunocytology assay that may be reimbursable as an adjunct to cystoscopy or cytology in monitoring individuals with bladder cancer; not reimbursable for hematuria evaluation, screening asymptomatic individuals, diagnosing symptomatic individuals, or other unlisted indications.
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyUrinary Tumor Markers for Bladder Cancer
    Policy CodePolicy CPCPLAB038
    Change TypeCode removals
    Effective DateMay 1, 2026
    Last ReviewJan 12, 2026
    Next Review Date
    Key ActionReview plan-specific coverage documents and submit accurate documentation to support claims and code use.
    SourceLink
    On This Page
    Coverage Criteria for Urinary Tumor MarkersProcedure and Billing CodesProvider Responsibilities and Billing GuidanceBackgroundDefinitions
  1. Claims are subject to code edit protocols and claim review; providers may be asked to submit additional documentation upon request.
  2. Prior Authorization

    Provider action highlight

    Submit additional documentation promptly when requested to support medical necessity, coding, or billing. Failure to provide requested records may result in claim denial or recoupment.

    • Maintain and provide clinical records that justify the test order, indication, and relation to diagnosis or monitoring.
    • If requested, include cytology/cystoscopy findings, prior pathology, surveillance history, and clinical notes supporting use of urinary biomarker testing.
    Denial Risk

    Not reimbursable indications (provider-facing)

    Tests billed for evaluation of hematuria to screen asymptomatic individuals, to diagnose symptomatic individuals, or for other non-covered indications are not reimbursable.

    • Urinary biomarkers (BTA, NMP22, UroVysion FISH) and fluorescence immunocytology (ImmunoCyt/uCyt) are not reimbursable when used for hematuria evaluation, asymptomatic screening, diagnosis of symptomatic individuals, or indications other than those expressly allowed.
    • Any other urinary tumor markers for bladder cancer not specifically listed as reimbursable are also not reimbursable.
    Other urinary tumor markersAny urinary tumor markers for bladder cancer not specifically named (BTA, NMP22, UroVysion, ImmunoCyt) are stated as not reimbursable.